Join ITIF on Capitol Hill for a timely discussion on how GLP-1 therapies can transform health and economic outcomes—and what policymakers should do to maximize their benefits.

This forum shall explore how Argentina might accelerate growth in its life sciences sector while improving patient access to innovative medicines. It will examine the critical role of strong intellectual property frameworks and efficient regulatory systems in fostering local innovation and promoting local biomanufacturing. We will also explore how university technology transfer can leverage Argentina's established biotechnology expertise to drive sector development and economic growth.

This in-person event on Capitol Hill explored how academic research, entrepreneurship, and public-private partnerships are shaping innovation ecosystems—and what is needed to strengthen them going forward.

Watch now for an event releasing a report by ITIF, the Geneva Network, and the University of Akron School of Law profiling 24 pioneering case studies from five regions—Latin America, Africa, South Asia, Southeast Asia, and Middle East and North Africa—where IP rights have enabled innovators to create impactful health solutions, particularly in the developing world.

Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.

The White House’s AI Action Plan highlights how upgrading labs, data infrastructure, and research models is essential to unlock AI’s full potential in accelerating drug discovery and keeping the United States at the forefront of biopharmaceutical innovation.

A cornerstone of U.S. biopharmaceutical leadership, PDUFA has dramatically accelerated drug approvals and patient access, but looming FDA budget cuts threaten to unravel three decades of progress.

Microgravity could be the next big breakthrough in drug development, but only if policymakers act now to turn space-based research from potential into progress.

The Trump administration’s call for “most favored nation” drug price controls will lead to less biopharmaceutical innovation and reduced U.S. drug industry competitiveness. However, the president’s willingness to use tariff negotiations to press other nations to pay their fair share for patented drugs is salutary.

To stay ahead in biopharma and ensure new therapies work for everyone, the U.S. must fix the diversity gap in biomedical research.

Recent policies permitting CMS price setting are hamstringing the U.S. biopharmaceutical industry, as they reduce incentives for pharmaceutical companies to invest in future drug R&D to create life-improving and life-saving medicines.

The Inflation Reduction Act (IRA) undermines innovation in small-molecule drugs by subjecting them to price controls after 9 years, whereas large-molecule drugs (biologics) are allowed 13 years of market pricing. Congress should pass the bipartisan EPIC Act to remedy this issue.